Express Pharma

Indian pharma needs to balance innovation, scale and integration for sustained growth 

Dr Simta Jadhav, VP, Raay Neopharma, highlights how AI, formulation-led research and backward integration could shape the next phase of Indian pharma’s growth, and discusses why companies need to rethink R&D investment, risk and long-term planning, in an in-person interaction with Neha Aathavale 

0 15

India built much of its global pharmaceutical position on the ability to manufacture affordable generics. But as competition increases and the economics of conventional generics come under pressure, is formulation-led innovation becoming the next logical growth engine for Indian pharma? 

Absolutely yes, considering the current market dynamics and geopolitical uncertainties, I believe formulation-led research is no longer just a logical progression for the Indian pharmaceutical industry; it has become a strategic necessity.

There are two major reasons driving this shift. First, the increasing price competition and commoditisation of generics are making it difficult for companies to sustain profitability by relying on volume alone. To remain competitive, companies need to differentiate their products through advanced formulations, improved drug delivery systems and complex generics that offer greater value.

Second, government support and enabling policies are becoming increasingly important in encouraging innovation. Initiatives such as the Promotion of Research and Innovation in PharmaMedTech Sector (PRIP) scheme have created opportunities for pharmaceutical companies, including established industry players, to strengthen their R&D capabilities and participate in innovation.

Given the substantial investment and risk associated with developing new chemical entities, formulation-led research offers Indian companies a more practical pathway to build on their existing expertise while developing differentiated, commercially viable products.

Therefore, I believe we will see a stronger shift towards formulation-led innovation in the coming years. This is not to say that new chemical entity research is unimportant, but rather that formulation-led research aligns more closely with the capabilities and commercial realities of many Indian pharmaceutical companies today.

Ultimately, formulation led innovation is no longer simply an opportunity for growth; it is becoming essential for competitiveness, sustainability and the long term survival of Indian pharmaceutical companies.

India is increasingly being spoken about as a potential innovation hub rather than only the ‘pharmacy of the world’.

What, in your view, needs to change within pharma companies themselves for that transition to happen, particularly in how R&D is funded, evaluated and given room to take risks? 

Speaking from my experience in R&D, I believe Indian pharma needs to strike the right balance between its traditional strengths and the changing demands of the industry.

Since 2010, Indian pharmaceutical companies have largely built their growth on the generics business, particularly exports to the US. However, with changing trade policies, increasing competition and saturation in several generic segments, the industry is now moving towards complex generics and more differentiated products.

In this scenario, I believe Indian companies should increasingly focus on formulation-led innovation rather than immediately moving towards new chemical entities (NCEs), which require significantly higher R&D investments and involve greater financial risks. By leveraging our existing strengths in formulation development, drug delivery systems and complex generics, we can build differentiated products without necessarily taking on the investment burden associated with developing a completely new molecule.

However, beyond investment, one of the most important changes required is to build a culture of innovation within Indian pharmaceutical companies. Innovation should not be viewed as an occasional initiative but as an integral part of the organisation’s R&D strategy.

Equally important is developing a culture that accepts risk and failure as part of the innovation process. In research, not every project will succeed, and not every investment will translate into a commercial product. A project that fails can still provide valuable scientific insights and learning for future development. Instead of treating failure as a reason to terminate the innovation journey, companies should view it as an opportunity to learn, reassess and improve their approach.

Ultimately, the future of Indian pharma will depend not only on how much we invest in R&D, but also on how effectively we innovate, differentiate our products and learn from our experiences. We need to move from being purely volume-driven generic players to innovation-led companies, while continuing to leverage our existing strengths in manufacturing, affordability and formulation expertise.

What do you think might be the major reasons for many companies to downsize their R&D? 

From what I have observed, the current downsizing across several pharmaceutical companies is closely linked to the challenges in their export businesses in specific US market. Traditionally, companies have followed a growth trajectory that begins with the domestic market, expands into the emerging markets, and eventually moves into highly regulated markets such as the US and Europe.

Since around 2010, India has established itself as a major player in the global generics market. However, entering and sustaining a presence in US regulated markets has also meant dealing with increasing scrutiny around manufacturing practices, GMP compliance and product quality, particularly from the US FDA. In highly competitive segments, especially where generic products compete directly with innovator brands, regulatory compliance and manufacturing quality become critical factors. At the same time, the market has continued to operate under complex commercial and regulatory dynamics.

In my view, one of the major reasons for the current shift is the increasing saturation of the US generics market. Changing US trade policies, tariff-related uncertainties and intensifying competition are putting pressure on the traditional export-driven business model. Since export revenues have historically supported a significant portion of Indian pharmaceutical companies’ growth and R&D investments, any slowdown in this business directly affects their ability to sustain those investments.

The domestic market presents a different set of challenges. Price controls under the DPCO and regulation by the NPPA can limit the commercial returns companies achieve on certain formulations. Consequently, even when a company invests in formulation-led or innovation-led research, it may not be able to realise the same value from the product in India as it could in international markets. This creates a fundamental challenge: companies are expected to invest in innovation, but the commercial environment does not always allow them to recover those investments adequately.

Another important factor is the evolving regulatory landscape in Europe and the UK following Brexit. Regulatory requirements and submission pathways have changed, and companies may need to reassess their existing regulatory strategies, documentation and dossiers to meet the respective requirements. For example, a regulatory dossier or marketing authorisation approach previously used for the EU may not automatically be sufficient for the UK. Such changes can increase compliance costs, development timelines and the resources required to maintain market access.

Therefore, I believe the current reduction in R&D investment is not attributable to a single factor. It reflects a combination of saturation in the US generics market, changing trade policies, domestic price controls and evolving regulatory requirements across international markets.

Ultimately, the key challenge for Indian pharma is that the traditional exportdriven model, which helped fund growth and R&D for many years, is becoming more difficult to sustain. Companies now need to reassess their market strategies, diversify their revenue streams and focus on differentiated products and innovation, while ensuring that the commercial returns justify the investments required.

There is now a lot of talk about complex generics, differentiated drug delivery and reformulation as the middle ground between conventional generics and discovering a completely new molecule. Do you think Indian pharma is sufficiently willing to invest in this space, or is the industry still too focused on volume and speed to market? 

Here, I believe Indian pharma needs to strike the right balance between volume and innovation. Our traditional strength has been large-scale manufacturing and the ability to provide affordable medicines. However, with the US increasingly focusing on strengthening domestic manufacturing under its Make in America agenda, relying solely on scale and volume may not be a sustainable long-term strategy. We need to move up the value chain by investing more in innovation.

While India is making progress in this direction, the challenge lies in generating adequate returns on R&D investments, particularly when the domestic market alone may not be sufficient to justify the cost and risk involved. Developing a niche product does not necessarily translate into commercial success, and this uncertainty can act as a significant barrier to innovation.

At the same time, ensuring access to affordable medicines remains critical. The question is how we balance affordability with the need to create a commercially viable environment for innovation. This is where government policy becomes important— not just in encouraging R&D investments, but also in creating mechanisms that enable companies to recover those investments and generate sustainable returns.

Ultimately, we should not move away from our strength in generics and manufacturing scale; rather, we need to build on it by strengthening our innovation capabilities.

For a company trying to move beyond the conventional generics playbook, the challenge is not just developing a different product but deciding which problems are actually worth solving. From a leadership perspective, how do you decide where to take an R&D bet and where not to? 

From an R&D and leadership perspective, I believe the first step is to clearly understand an organisation’s core capabilities and strengths. Every company has its own areas of expertise, and strategic decisions should be built around those strengths rather than driven purely by industry trends. For instance, biologics and biosimilars are receiving significant attention today, but that does not necessarily mean every company should enter these segments without first assessing its capabilities and preparedness.

One of the key challenges is the availability of skilled talent. While biotechnology is gaining momentum in India, the pool of professionals with deep, hands-on experience in biologics and biosimilars remains relatively limited compared with the established expertise available in conventional formulation development. Some companies have already invested in these areas, but building the necessary technical capabilities and developing a skilled workforce takes time.

Therefore, as leaders, we need to take a two-pronged approach. First, we should strengthen our existing core competencies through innovation, platform technologies and formulation-led research that can create differentiation and establish a sustainable competitive advantage. Second, if we want to enter emerging areas such as biologics and biosimilars, we must invest in the right talent, technical expertise and infrastructure required to succeed.

Equally important is the need to evaluate the commercial viability of every R&D investment right from the beginning. We must assess the investment required, the development timelines, the market potential, the expected returns and the competitive landscape. In the generics business, for example, understanding the market forecast, anticipated price erosion and the likely entry of other generic players is critical to making informed decisions.

We often see projects being put on hold or discontinued after substantial investments have already been made. This can happen when the initial assessment does not adequately account for development costs, commercial risks or changes in market dynamics. By the time a product is ready for launch, the market opportunity may have diminished significantly.

Ultimately, leadership in R&D is not just about deciding what to develop; it is about deciding where to invest, when to invest and whether the investment can deliver sustainable value. A thorough assessment of technical capabilities, talent, timelines, financial commitments and market potential is essential to ensure that innovation is not only scientifically successful but also commercially viable. This is how companies can protect their resources, minimise risks and build a sustainable R&D pipeline for long-term growth.

If you look five to ten years ahead, what do you think will distinguish the Indian pharma companies that successfully move up the value chain from those that remain dependent on the traditional generics model? And what leadership choices need to be made now to get there?

Looking ahead over the next five to ten years, I believe AI will play a transformative role in the pharmaceutical industry, much like the impact we have already witnessed in the software sector.

We are already seeing a shift in how AI platforms are being developed and applied across pharmaceutical R&D. Initially, the focus was largely on compatibility, but today, these platforms are expanding into areas such as formulation stability prediction, clinical study outcomes and biopredictability. For instance, in formulation development, AI-driven platforms have the potential to significantly reduce the number of experimental trials required. What might traditionally take 10 to 15 trials could potentially be narrowed down to just two or three targeted experiments, depending on the formulation and the complexity of the product. Several excipient companies are also developing platforms based on Biopharmaceutics Classification System (BCS) principles, offering ready-to-use formulation approaches that companies can further optimise for their specific requirements. Similar advancements are taking place in predicting in-vivo performance and biopredictability.

Therefore, adopting AI will increasingly become a strategic necessity rather than simply a technological advantage. However, successful adoption will depend not only on the availability of these platforms but also on hiring the right talent, building internal capabilities and integrating AI effectively into existing R&D workflows. 

Another major challenge for pharmaceutical innovation is backward integration and the security of the supply chain, particularly for active pharmaceutical ingredients (APIs), key starting materials and other critical raw materials. Geopolitical disruptions, including conflicts in regions such as West Asia, have highlighted how vulnerable supply chains can be. In some cases, sourcing APIs, raw materials or even specific impurities can take three to four months, potentially delaying development timelines and product launches.

Therefore, going forward, pharmaceutical companies need to focus on two critical priorities: leveraging AI to improve the speed and efficiency of R&D, and strengthening supply-chain resilience through better sourcing strategies and backward integration wherever commercially viable. Ultimately, the future competitiveness of Indian pharma will depend on how effectively we combine technology-driven innovation with supply-chain security. AI can help us develop products faster and more efficiently, while stronger control over critical raw materials can help ensure that these innovations reach the market without unnecessary delays. 



[email protected]
[email protected]

 

Leave A Reply

Your email address will not be published.